MBT
ALXN

Monroe Bank & Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Monroe Bank & Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-24
Closed -$3K – 326
2016
Q1 		$3K Buy
+24
New +$3.52K ﹤0.01% 351

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Monroe Bank & Trust's ALXN Position: Q2 2016 in Review

Monroe Bank & Trust sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 24 shares — an estimated $3K sold.

Monroe Bank & Trust first reported a position in ALXN in Q1 2016 and held it in 1 quarter. The position peaked at $3K in Q1 2016. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Monroe Bank & Trust reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Monroe Bank & Trust sold 24 Alexion Pharmaceuticals shares in Q2 2016, an estimated $3K.
  • Monroe Bank & Trust first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Monroe Bank & Trust's Alexion Pharmaceuticals position peaked at $3K in Q1 2016.
  • 533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Monroe Bank & Trust's 13F filing for Q2 2016, filed 10 Aug 2016.